Atasu Nayak, MD
Interventional Cardiology · Houston, TXNPI 1568558740
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 31.0% of the total. Reporting peaked in 2022 at $3,292 and has fallen 77.6% since, to $737 in 2025. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.
Across 103 payments — averaging $78.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Abbott$2K
- Boston Scientific$854
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$641
- Medtronic$542
- Shockwave Medical, Inc$341
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$2,50031%
- Travel & lodging$79610%
- Food & beverage$4,54056%
- Education$2233%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $2,500 |
| Abbott | 16 | $1,603 |
| Boston Scientific | 9 | $854 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $641 |
| Medtronic(2 entities) | 8 | $542 |
| Shockwave Medical, Inc | 5 | $341 |
| Impulse Dynamics (USA) Inc. | 4 | $285 |
| Amgen | 10 | $176 |
| Edwards Lifesciences | 1 | $134 |
| Penumbra, Inc. | 1 | $130 |
| Angiodynamics, Inc. | 1 | $122 |
| Philips North America LLC | 1 | $120 |
| Silk Road Medical, Inc. | 1 | $97 |
| Novartis | 4 | $90 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Johnson & Johnson | 3 | $77 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Bridgebio Pharma, Inc. | 1 | $38 |
| Pfizer | 2 | $34 |
| Chiesi USA, Inc. | 2 | $34 |
| Cardiva Medical, Inc. | 1 | $30 |
| AstraZeneca | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$2,500
- TRULANCE$2,500
- PLENVU$2,500
- SUPERA$974
- OPTIMIZER$304
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$269
- ClosureRFS$206
- COREVALVE EVOLUT R$158
- GENERAL - THERAPIES$154
- Ranger$151
- Indigo System$130
- AVVIGO Guidance System$126
- GENERAL VASCULAR INTERVENTION$123
- AngioVac$122
- (9520) IGT Devices Undivided$120
- EKOSONIC$104
How this compares
$8,059 in reported general payments places this provider in the 45th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 451 | $430,713 |
| EntrestoSacubitril/Valsartan | 58 | $61,015 |
| XareltoRivaroxaban | 50 | $55,916 |
| Atorvastatin Calcium | 968 | $31,541 |
| Ezetimibe | 183 | $24,672 |
| BrilintaTicagrelor | 29 | $23,367 |
| Repatha SureclickEvolocumab | 20 | $18,250 |
| ClopidogrelClopidogrel Bisulfate | 554 | $14,295 |
| Praluent PenAlirocumab | 21 | $13,923 |
| Rosuvastatin Calcium | 259 | $13,077 |
| Metoprolol Succinate | 416 | $12,127 |
| Losartan Potassium | 393 | $12,055 |
| Repatha SyringeEvolocumab | 17 | $11,221 |
| Carvedilol | 449 | $8,637 |
| Pravastatin Sodium | 171 | $7,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $34 | $430,713451 claims |
| NovartisEntresto | $90 | $61,01558 claims |
| Johnson & JohnsonXarelto | $77 | $55,91650 claims |
| AstraZenecaBrilinta | $27 | $23,36729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Michele SartoriHouston$266K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.